This proposal is designed to evaluate mechanisms of antitumor activity of IL2 or IL2 and human IL-2-activated effector cells in a series of in vitro studies and in vivo utilizing an animal model established in our laboratory. The model involves xenografting human oral squamous cell carcinoma (SCC) cell lines into immunosuppressed BALB/c nude mice (splendectomized and pretreated with cyclophosphamide and anti-asialo GMI antibody). The tumors, which develop following subcutaneous injection of sufficient numbers of tumor cells in these mice, histologically resemble the original human tumors. The model has been used by us to demonstrate that established SCC could be induced to regress completely as a result of local administration of interleukin 2 (IL2) plus human natural killer (A-NK) cells. Tumor regression was also induce by supernatants (SN) of A-NK cells in injected perilesionally to mice bearing established SCC. Our observation that SC of the head and neck (SCCHN) express functional receptors for IL2 (IL2R) and that IL2 inhibits growth of SCCHN cell lines in vitro and of established tumors in vivo, provide a strong rationale for further investigating direct effects of IL2 on tumor growth. The role of IL2R in IL2-induced tumor growth inhibition will be explored by studying expression of high-affinity (a,B,y) and intermediate-affinity (B,gamma) IL2R on SCCHN cell lines relative to the level of proliferation inhibition by IL2. Cell cycle analysis will be used to determine the proportion of tumor cells arrested in the G/G1 phase in the presence of IL2. SCCHN cell lines will be transfected with the IL2-a and gamma chain genes or anti-sense IL2R-B chain gene to alter tumor cell responsiveness to growth inhibitory effects of IL2. Tumor transfectants will be evaluated first in vitro and the in vivo for IL-2-mediated growth inhibition. In vivo locoregional delivery of IL-2, IL2 plus effector cells or SN or A-NK cells to SCC transfectants and parental tumors established in nude mice is expected to result in tumor regression. Therapeutic of IL2, SN or IL2 plus effector cells will be compared in this in vivo model, and tumor regression or extended survival of treated mice will be used as endpoints to optimize local immunotherapy. SCC will be transfected with the IL2 gene and implanted into animals. The tumor transfectants are expected to produce IL2, so that both autocrine IL2R-mediated cytostatic effects of IL2 and its immunostimulatory effects on adoptively transferred effector cells can be compared. To evaluate the biologic role of IL2R on human SCCHN, in situ expression of IL2R on rat mucosal epithelium, primary and recurrent SCC in the oral cavity and oropharynx will be determined by immunoperoxidase in situ hybridization, using fresh biopsy tissue. Expression of IL2R will be related to that of epidermal growth factor receptor (EGFR) and its ligand, EGF. In situ result should therapeutic efficacy of IL2 in the xenograft tumor model may lead to development of novel strategies for treatment of human SCCHN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA063513-01
Application #
2105411
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Project Start
1994-06-10
Project End
1997-05-31
Budget Start
1994-06-10
Budget End
1995-05-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kuhn, Deborah J; Smith, David M; Pross, Seth et al. (2003) Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability. J Cell Biochem 89:824-36
Whiteside, Theresa L; Gambotto, Andrea; Albers, Andreas et al. (2002) Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. Proc Natl Acad Sci U S A 99:9415-20
Reichert, T E; Nagashima, S; Kashii, Y et al. (2000) Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 19:514-25
Reichert, T E; Kashii, Y; Stanson, J et al. (1999) The role of endogenous interleukin-2 in proliferation of human carcinoma cell lines. Br J Cancer 81:822-31
Kashii, Y; Giorda, R; Herberman, R B et al. (1999) Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163:5358-66
Nagashima, S; Mailliard, R; Kashii, Y et al. (1998) Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91:3850-61
Lang, S; Vujanovic, N L; Wollenberg, B et al. (1998) Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells. Eur J Immunol 28:780-6
Whiteside, T L; Sung, M W; Nagashima, S et al. (1998) Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Clin Cancer Res 4:1135-45
Reichert, T E; Watkins, S; Stanson, J et al. (1998) Endogenous IL-2 in cancer cells: a marker of cellular proliferation. J Histochem Cytochem 46:603-11
Reichert, T E; Rabinowich, H; Johnson, J T et al. (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21:295-306

Showing the most recent 10 out of 21 publications